Objective response rate assessment in oncology: current situation and future expectations

Basit Öğe Kaydı
dc.authoridNuri Faruk Aykan / 0000-0002-5472-3218
dc.authoridTahsin Özatlı / 0000-0002-8563-3856
dc.authorscopusidNuri Faruk Aykan / 57219836263
dc.authorscopusidTahsin Özatlı / 16507471000
dc.authorwosidNuri Faruk Ayhan / I-6425-2019
dc.authorwosidTahsin Özatlı / DKU-3170-2022
dc.contributor.authorAykan, Nuri Faruk
dc.contributor.authorÖzatlı, Tahsin
dc.date.accessioned2020-08-30T20:06:15Z
dc.date.available2020-08-30T20:06:15Z
dc.date.issued2020
dc.departmentİstinye Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.description.abstractThe tumor objective response rate (ORR) is an important parameter to demonstrate the efficacy of a treatment in oncology. The ORR is valuable for clinical decision making in routine practice and a significant end-point for reporting the results of clinical trials. World Health Organization and Response Evaluation Criteria in Solid Tumors (RECIST) are anatomic response criteria developed mainly for cytotoxic chemotherapy. These criteria are based on the visual assessment of tumor size in morphological images provided by computed tomography (CT) or magnetic resonance imaging. Anatomic response criteria may not be optimal for biologic agents, some disease sites, and some regional therapies. Consequently, modifications of RECIST, Choi criteria and Morphologic response criteria were developed based on the concept of the evaluation of viable tumors. Despite its limitations, RECIST v1.1 is validated in prospective studies, is widely accepted by regulatory agencies and has recently shown good performance for targeted cancer agents. Finally, some alternatives of RECIST were developed as immune-specific response criteria for checkpoint inhibitors. Immune RECIST criteria are based essentially on defining true progressive disease after a confirmatory imaging. Some graphical methods may be useful to show longitudinal change in the tumor burden over time. Tumor tissue is a tridimensional heterogenous mass, and tumor shrinkage is not always symmetrical; thus, metabolic response assessments using positron emission tomography (PET) or PET/CT may reflect the viability of cancer cells or functional changes evolving after anticancer treatments. The metabolic response can show the benefit of a treatment earlier than anatomic shrinkage, possibly preventing delays in drug approval. Computer-assisted automated volumetric assessments, quantitative multimodality imaging in radiology, new tracers in nuclear medicine and finally artificial intelligence have great potential in future evaluations.en_US
dc.identifier.citationAykan, N. F., & Ozatli, T. (2020). Objective response rate assessment in oncology: Current situation and future expectations. WORLD JOURNAL OF CLINICAL ONCOLOGY, 11(2), 53–73. https://doi.org/10.5306/wjco.v11.i2.53en_US
dc.identifier.doi10.5306/wjco.v11.i2.53en_US
dc.identifier.endpage73en_US
dc.identifier.issn2218-4333en_US
dc.identifier.issue2en_US
dc.identifier.pmid32133275en_US
dc.identifier.startpage53en_US
dc.identifier.urihttps://doi.org/10.5306/wjco.v11.i2.53
dc.identifier.urihttps://hdl.handle.net/20.500.12713/443
dc.identifier.volume11en_US
dc.identifier.wosWOS:000518628500002en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorAykan, Nuri Faruken_US
dc.institutionauthorÖzatlı, Tahsinen_US
dc.language.isoenen_US
dc.publisherBaishideng Publishing Group Incen_US
dc.relation.ispartofWorld Journal of Clinical Oncologyen_US
dc.relation.publicationcategoryDiğeren_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectObjective Response Rateen_US
dc.subjectTumor Shrinkageen_US
dc.subjectWorld Health Organization Criteriaen_US
dc.subjectResponse Evaluation Criteria In Solid Tumorsen_US
dc.subjectImmune Response Evaluation Criteria In Solid Tumors Criteriaen_US
dc.subjectEarly Tumor Shrinkageen_US
dc.subjectDepth Of Responseen_US
dc.subjectWaterfall Ploten_US
dc.subjectSpider Ploten_US
dc.subjectSwimmer Ploten_US
dc.titleObjective response rate assessment in oncology: current situation and future expectationsen_US
dc.typeReview Articleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
WJCO-11-53.pdf
Boyut:
2.51 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Dahili Tıp Bilimleri Bölümü Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Tıbbi Görüntüleme Teknikleri Programı Makale Koleksiyonu